B7-H6产品信息
别称:B7-H6,NCR3LG1,B7 Homolog 6
物种:Human / Cynomolgus
属性:Protein / Antibody Licensing
标记:Biotin-labeled / Unconjugated
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>90% as determined by SDS-PAGE.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.
B7-H6分子背景
B7基因家族在调节适应性免疫系统中至关重要。其中之一是最近发现的B7-H6。人类和大鼠只有一个B7-H6基因;然而,在爪蟾基因组中的单个大簇中检测到许多B7-H6基因。嵌合抗原受体(CAR)T细胞疗法在临床试验中已被证明对B细胞白血病具有持久和潜在的疗效。在这项研究中,靶向NK细胞激活受体NKp30的配体B7-H6,以创建靶向多种肿瘤类型的CAR。B7-H6在各种原发性人类肿瘤上表达,包括白血病、淋巴瘤和胃肠道间质瘤,但在正常组织上不是组成型表达的。
B7-H6用户评价
关键字: B7-H6;B7-H6蛋白;B7 Homolog 6;B7H6;B7H6蛋白;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。